

RECEIVED
CENTRAL FAX CENTER

MAY 05 2006

Attorney Docket No.: 10295.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jorgensen et al.

Confirmation No: 9822

Serial No.: 10/510,408

Group Art Unit: 1636

Filed: October 5, 2004

Examiner: Vogel

For: Improved Bacillus Host Cell

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Supplemental Response to Restriction Requirement

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Vogel, fax number (571) 273-8300 .

Date: May 5, 2006

Respectfully submitted,



Lourdes Ayala
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

RECEIVED
CENTRAL FAX CENTER

MAY 05 2006

Attorney Docket No.: 10295.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jorgensen et al.

Confirmation No: 9822

Serial No.: 10/510,408

Group Art Unit: 1636

Filed: October 5, 2004

Examiner: Vogel

For: Improved Bacillus Host Cell

SUPPLEMENTAL RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


This paper is filed in response to the Office Action mailed April 6, 2006 that indicated that the response to restriction and election of species requirements was **non-responsive** because Applicant identified SEQ ID NO:1, which is not present in the claims.

The undersigned attorney apologizes for the inconvenience caused by this typographical error. Applicants hereby elect the invention of Group I, SEQ ID NO:2. Applicants hereby reserve the right to file continuing applications directed to the non-elected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: May 5, 2006



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097